Biocon to merge Biocon Biologics in $5.5 billion deal

Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million

Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma

The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population

Lupin inks US licensing deal with Valorum for biosimilar Armlupeg

Valorum will advance the commercialization and distribution of Armlupeg in the United States

Senores Pharmaceuticals receives Philippine FDA approval for 10 products

Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region

Kytopen & TQ Therapeutics forge partnership to advance next-generation cell therapies

The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology

Wellcome injects £2 million to turbocharge UK regulation of digital mental health tech

Philips unveils helium-free 3.0T MRI innovation at RSNA 2025

The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology

Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy

Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib

Eli Lilly pledges $40 million to Indiana University to expand clinical trials

The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy

FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment

Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor